Senseonics Holdings Inc. launched its 90-day implantable continuous glucose monitoring (CGM) system in the U.S. Starting July 31, it has been injecting its sensors in the market for U.S. patients. Now, Senseonics needs to secure its reimbursement pathway, which may differ from more established wearable CGM competitors Abbott Laboratories and Dexcom Inc. Read More
PERTH, Australia – New Australian and European guidelines on managing sexually transmitted diseases (STDs) are driving demand for Speedx Ltd.'s molecular diagnostic that simultaneously detects the Mycoplasma genitalium bacteria and the genetic markers linked to antimicrobial resistance. Read More
